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1717As is pointed out in the editorial, both the recent
American College of Cardiology/American Heart
Association and the European Society of Cardiology
guidelines recommend prasugrel in NSTEMI only
after angiography, and this fact places prasugrel as a
second-line agent. Although prasugrel showed beneﬁt
over clopidogrel in the TRITON (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel), the design of the
trial was criticized due to the 300-mg loading dose of
clopidogrel and also the administration after angiog-
raphy instead of earlier, probably limiting the effect of
clopidogrel, the effect of which takes longer to act.
In our opinion, the right comparison between
prasugrel and clopidogrel in NSTEMI has still not
been carried out. If we review both the results of the
CREDO (Clopidogrel Maintaining Dosage in Acute
Coronary Syndrome After Drug Eluting Stent Im-
plantation) and ACCOAST, we can assume that the
best moment to initiate clopidogrel would be as soon
as possible after admission and just after the initial
angiography for prasugrel. Both drugs have theoret-
ical advantages such as an unrestricted spectrum of
patients (4,5), fewer bleeding events, more experience
with the drug, and lower cost of clopidogrel versus
more rapid onset and action, a reduction in nonfatal
coronary events and stent thrombosis, and avoiding
the administration of the drug in patients who would
need surgery once the anatomy is known for prasu-
grel. Although it is highly improbable that a prospec-
tive and adequately powered study will be designed
8 years after the publication of the TRITON trial and
with the presence of ticagrelor in the market, we
believe that the only way to have the correct answer
for prasugrel and clopidogrel in NSTEMI would be to
compare in ischemic and bleeding events the pre-
treatment with clopidogrel with the administration
of prasugrel after the initial angiography, and it would
probably be the only way for prasugrel to once again
become a ﬁrst-line treatment for these patients.*Iñigo Lozano, MD, PhD
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Correctly With Clopidogrel in
Non–ST-Segment Elevation
Acute Coronary Syndrome?We thank Dr. Lozano and colleagues for their interest
in our paper. However, they misinterpret the results
of the ACCOAST (Comparison of Prasugrel at PCI or
Time of Diagnosis of Non-ST Elevation Myocardial
Infarction) and of the preceding trials. Placing the
new P2Y12 antagonists in general and prasugrel in
particular as a second-line treatment in non–ST-
segment elevation myocardial infarction (NSTEMI)
does not reﬂect the superiority demonstrated by
these new drugs over clopidogrel in 2 pivotal trials. It
does not comply with the current guidelines, espe-
cially for the patients undergoing percutaneous cor-
onary intervention, as both prasugrel and ticagrelor
have a class I recommendation, whereas clopidogrel
should be given “only when prasugrel or ticagrelor
are not available or are contraindicated” (1). So the
ﬁrst error is to believe that clopidogrel is still the gold
standard for the treatment of NSTEMI.
The second error is to believe that pre-treatment
with a P2Y12 antagonist is of beneﬁt to NSTEMI
patients. Pre-treatment is a treatment given to the
patients while they wait to undergo coronary angiog-
raphy. Although Dr. Lozano thinks that this is the right
thing to do with clopidogrel, it has never been vali-
dated by a randomized study. This question of clopi-
dogrel pre-treatment was not evaluated in the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent
Events) study because the majority of patients did not
have coronary angiography performed in this study. It
was also not addressed by the CREDO (Clopidogrel for
the Reduction of Events During Observation) study
because the coronary status of the majority of patients
was known at the time of randomization (2). No study
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1718evaluated pre-treatment with ticagrelor. So the only
randomized trial to evaluate pre-treatment is the
ACCOAST study, which showed harm and no beneﬁt to
the patients with pre-treatment.
Finally, despite the caveats of the CURE and
CREDO trials, which favor pretreatment without
really testing the hypothesis, when pooling the data
from ACCOAST, CURE, and CREDO trials (N > 18,000),
there was no decrease in mortality or ischemic
events, but a signiﬁcant 45% excess of major bleeding
with thienopyridine pre-treatment (3). Both clopi-
dogrel and pre-treatment are strategies of the past
(4). However, we encourage Dr. Lozano to perform
the study that he suggests in his conclusion.*Gilles Montalescot, MD, PhD
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Created EqualWe commend the authors of the recently published
ACCOAST-PCI (A Comparison of Prasugrel at the
Time of Percutaneous Coronary Intervention or as
Pre-treatment At the Time of Diagnosis in Patients
with Non-ST-Elevation Myocardial Infarction) study
(1) for their efforts. Despite being the largest
randomized trial of pre-treatment with prasugrelin non–ST-segment elevation myocardial infarction
(NSTEMI) patients, we have reservations that we
detail as follows.
Risk stratiﬁcation for adverse cardiac events is a key
component of treating NSTEMI patients. In this trial,
w57% of patients presentedwith ischemic ST-segment
changes and w23% with a GRACE (Global Registry of
Acute Coronary Events) score of more than 140. It
would be interesting to know the event rates in these
patients stratiﬁed according to whether they were
pre-treated with prasugrel or not. Ischemic events are
higher in patients with ischemic ST-segment changes
and/or high GRACE score, which may warrant more
aggressive therapy to improve outcomes (2).
The event rates for stent thrombosis were
extremely low, <0.5%. Because the trial was not
powered to show the differences between both
strategies, no real conclusions can be drawn about
stent thrombosis and the association with pre-
treatment with prasugrel other than numerically
there were fewer events in the pre-treatment group.*Ramez Nairooz, MD
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e139–228.REPLY: Not All NSTEMIs Are Created EqualTo answer the comments of Dr. Nairooz and col-
leagues, we have performed additional analyses of
the percutaneous coronary intervention subgroup
that need to be examined with caution considering
their post-hoc nature. Although it is possible to
evaluate the individual risk of a patient presenting
with a non–ST-segment elevation myocardial infarc-
tion according to well-known factors or scores, mak-
ing the decision to pre-treat or not, according to this
evaluation does not seem appropriate. The GRACE
